• CDC Director Dr. Tom Frieden provides insight to the spread of Ebola, and announces an individual traveling from Liberia to the United States has been diagnosed with Ebola in Texas.

  • Sarepta CEO ready with Ebola drug if requested     Tuesday, 30 Sep 2014 | 5:29 PM ET

    Sarepta President and CEO Chris Garabedian says his company has enough clinical trial quality drug on hand to treat a couple dozen Ebola patients if requested.

  • CNBC's Meg Tirrell reports Texas health officials have confirmed the Ebola patient is in Texas, and had a recent history of travel to West Africa.

  • Ebola stocks surge after first US case diagnosed Tuesday, 30 Sep 2014 | 5:04 PM ET
    The Centers for Disease Control sign is seen at its main facility in Atlanta, Georgia.

    Shares of pharmaceutical companies working on a drug to treat Ebola spiked after the CDC confirmed the first case diagnosed in the U.S.

  • Pharma companies spike ahead of CDC newser     Tuesday, 30 Sep 2014 | 5:03 PM ET

    The CDC has confirmed the first Ebola case diagnosed in the U.S. The "Fast Money" traders discuss the companies spiking on the news.

  • First Ebola case confirmed in US     Tuesday, 30 Sep 2014 | 5:00 PM ET

    The CDC has confirmed the first Ebola case diagnosed in the U.S. and will hold a news conference at 5:30PM E.T. Tuesday. CNBC's Meg Tirrell has the details.

  • CDC confirms first Ebola case in US     Tuesday, 30 Sep 2014 | 4:44 PM ET

    The CDC will hold a news conference on a U.S. Ebola case at 5:30PM E.T., reports CNBC's Dominic Chu.

  • Joe Namath tackles head injuries     Tuesday, 30 Sep 2014 | 3:42 PM ET

    Former NFL quarterback Joe Namath is taking on the fight against debilitating effects of brain injuries.

  • Sept 30- Johnson& Johnson agreed to pay $1.75 billion in cash to buy privately held Alios BioPharma Inc, which is developing a drug for a common respiratory viral infection in children for which there is no approved treatment.

  • Regeneron, Sanofi say sinusitis drug met goals Tuesday, 30 Sep 2014 | 11:56 AM ET

    NEW YORK— Drugmakers Regeneron Pharmaceuticals and Sanofi said Tuesday that an experimental drug reduced symptoms of chronic sinusitis in a clinical trial. Shares of Regeneron Pharmaceuticals Inc. rose $5.26 to $306.22 in morning trading. Sanofi stock added $1 to $56.71.

  • Sept 30- Johnson& Johnson said it would buy privately held drug developer Alios BioPharma Inc for $1.75 billion in cash, to access a portfolio of drugs targeting viral infections. Johnson& Johnson said the deal includes Alios's experimental drug for infants with respiratory syncytial virus.

  • MADRID, Sept 30- A raft of new cancer drugs promise better, longer-lasting treatments with fewer adverse side effects-- but their high cost is a growing concern. Price-- just as much as safety and efficacy-- has proved a hot topic for nearly 20,000 oncology experts at the European Society for Medical Oncology annual congress in Madrid.

  • Viagra ads target women for 1st time Tuesday, 30 Sep 2014 | 5:02 AM ET

    TRENTON, N.J.— The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial that targets the less-obvious sufferers of the sexual condition: women. Having a woman speak directly to men about impotence is a unique strategy for Pfizer Inc. The world's second-biggest drugmaker is looking for ways to...

  • Sept 29- Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated with a rare autoimmune disorder, compared with a placebo.

  • Sept 29- Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated with a rare autoimmune disorder, compared with a placebo.

  • AP Top Extended Financial Headlines At 3:10 p.m. EDT Monday, 29 Sep 2014 | 3:10 PM ET

    Toyota recalls 690,000 Tacoma pickups; rear leaf springs can fracture and puncture gas tank US stocks head lower following drops in Europe and Asia US consumer spending climbed healthy 0.5 percent in August, while income up 0.3 percent Fewer signed contracts point to weak home sales over next few months Using another bank's ATM keeps costing you more, an average of $4.35 for each transaction US safety agency looking into low-speed unintended acceleration in older Toyota Corollas Attorneys says death toll from GM ignition switches now at 23 SEC says Bank of America will pay $7.65 M to end inquiry into errors in report to Fed Canada's Encana buying Athlon Energy for $5.93 B, gets strong position in Permian Basin Clovis Oncology rises on results from study of rucaparib as a treatment for ovarian cancer

  • Clovis shares rise on ovarian cancer study data Monday, 29 Sep 2014 | 3:09 PM ET

    NEW YORK— Shares of Clovis Oncology climbed Monday after the company reported promising study results for its cancer drug rucaparib. Clovis Oncology said Monday that in a small trial, 14 out of 15 patients had stable disease levels or experienced tumor shrinkage for at least 12 weeks.

  • WASHINGTON, Sept 29- Bras, girdles and leggings infused with caffeine and sold as weight loss aids were more decaf than espresso, and the companies that sold them have agreed to refund money to customers and pull their ads, U.S. regulators said on Monday.

  • Sept 29- Amag Pharmaceuticals Inc entered the women's healthcare business by acquiring privately held Lumara Health Inc for $675 million in its biggest deal ever, sending its shares up as much as 23 percent to a four-year high.

  • *Roche set to compete with established GSK combination. *Shares in Roche's biotech partner Exelixis jump 20 pct. MADRID, Sept 29- Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the two skin cancer courses.